Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis.
Adverse effects
CKD
Elderly
Multimorbidity
Polypharmacy
Prescriptions
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
04 07 2021
04 07 2021
Historique:
received:
26
11
2020
accepted:
23
06
2021
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Polypharmacy, often defined as the concomitant use of ≥ 5 medications, has been identified as a significant global public health threat. Aging and multimorbidity are key drivers of polypharmacy and have been linked to a broad range of adverse health outcomes and mortality. Patients with chronic kidney disease (CKD) are particularly at high risk of polypharmacy and use of potentially inappropriate medications given the numerous risk factors and complications associated with CKD. The aim of this systematic review will be to assess the prevalence of polypharmacy among adult patients with CKD, and the potential association between polypharmacy and adverse health outcomes within this population. We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and PsycINFO and grey literature from inception onwards (with no language restrictions) for observational studies (e.g., cross-sectional or cohort studies) reporting the prevalence of polypharmacy in adult patients with CKD (all stages including dialysis). Two reviewers will independently screen all citations, full-text articles, and extract data. Potential conflicts will be resolved through discussion. The study methodological quality will be appraised using an appropriate tool. The primary outcome will be the prevalence of polypharmacy. Secondary outcomes will include any adverse health outcomes (e.g., worsening kidney function) in association with polypharmacy. If appropriate, we will conduct random effects meta-analysis of observational data to summarize the pooled prevalence of polypharmacy and the associations between polypharmacy and adverse outcomes. Statistical heterogeneity will be estimated using Cochran's Q and I Given that polypharmacy is a major and a growing public health issue, our findings will highlight the prevalence of polypharmacy, hazards associated with it, and medication thresholds associated with adverse outcomes in patients with CKD. Our study will also draw attention to the prognostic importance of improving medication practices as a key priority area to help minimize the use of inappropriate medications in patients with CKD. PROSPERO registration number: [ CRD42020206514 ].
Sections du résumé
BACKGROUND
Polypharmacy, often defined as the concomitant use of ≥ 5 medications, has been identified as a significant global public health threat. Aging and multimorbidity are key drivers of polypharmacy and have been linked to a broad range of adverse health outcomes and mortality. Patients with chronic kidney disease (CKD) are particularly at high risk of polypharmacy and use of potentially inappropriate medications given the numerous risk factors and complications associated with CKD. The aim of this systematic review will be to assess the prevalence of polypharmacy among adult patients with CKD, and the potential association between polypharmacy and adverse health outcomes within this population.
METHODS/DESIGN
We will search empirical databases such as MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and PsycINFO and grey literature from inception onwards (with no language restrictions) for observational studies (e.g., cross-sectional or cohort studies) reporting the prevalence of polypharmacy in adult patients with CKD (all stages including dialysis). Two reviewers will independently screen all citations, full-text articles, and extract data. Potential conflicts will be resolved through discussion. The study methodological quality will be appraised using an appropriate tool. The primary outcome will be the prevalence of polypharmacy. Secondary outcomes will include any adverse health outcomes (e.g., worsening kidney function) in association with polypharmacy. If appropriate, we will conduct random effects meta-analysis of observational data to summarize the pooled prevalence of polypharmacy and the associations between polypharmacy and adverse outcomes. Statistical heterogeneity will be estimated using Cochran's Q and I
DISCUSSION
Given that polypharmacy is a major and a growing public health issue, our findings will highlight the prevalence of polypharmacy, hazards associated with it, and medication thresholds associated with adverse outcomes in patients with CKD. Our study will also draw attention to the prognostic importance of improving medication practices as a key priority area to help minimize the use of inappropriate medications in patients with CKD.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO registration number: [ CRD42020206514 ].
Identifiants
pubmed: 34218816
doi: 10.1186/s13643-021-01752-z
pii: 10.1186/s13643-021-01752-z
pmc: PMC8256607
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Subventions
Organisme : CIHR
Pays : Canada
Références
Expert Opin Drug Saf. 2018 Dec;17(12):1185-1196
pubmed: 30540223
PLoS One. 2011;6(10):e25153
pubmed: 22039406
Kidney Blood Press Res. 2013;38(1):109-20
pubmed: 24642796
J Am Pharm Assoc (2003). 2017 Nov - Dec;57(6):729-738.e10
pubmed: 28784299
JAMA. 2015 Nov 3;314(17):1818-31
pubmed: 26529160
Ther Adv Drug Saf. 2020 Jun 12;11:2042098620933741
pubmed: 32587680
J Bras Nefrol. 2014 Jan-Mar;36(1):1-5
pubmed: 24676606
J Clin Epidemiol. 2021 Jun;134:103-112
pubmed: 33577987
Eur J Clin Pharmacol. 2009 Aug;65(8):757-73
pubmed: 19543887
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:661-681
pubmed: 31589822
J Am Geriatr Soc. 2015 Nov;63(11):2290-7
pubmed: 26503124
J Am Med Dir Assoc. 2015 Jun 1;16(6):535.e1-12
pubmed: 25869992
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):492-7
pubmed: 21788893
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Nephrol Dial Transplant. 2015 Mar;30(3):441-51
pubmed: 25271006
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
JAMA Intern Med. 2016 Apr;176(4):473-82
pubmed: 26998708
Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1085-1095
pubmed: 29934432
Ther Adv Drug Saf. 2015 Dec;6(6):212-33
pubmed: 26668713
JAMA. 2005 Aug 10;294(6):716-24
pubmed: 16091574
Healthc Q. 2015;18(1):11-3
pubmed: 26168384
Stat Med. 2002 Jun 15;21(11):1559-73
pubmed: 12111920
Clin Kidney J. 2019 May 24;12(5):663-672
pubmed: 31584562
Pharmacogenomics. 2003 May;4(3):231-9
pubmed: 12718713
Drug Saf. 2006;29(5):385-96
pubmed: 16689555
Br J Clin Pharmacol. 2018 Dec;84(12):2811-2823
pubmed: 30110711
Drugs Aging. 2018 Aug;35(8):735-750
pubmed: 30039344
Nephrol Dial Transplant. 2006 Nov;21(11):3164-71
pubmed: 16880181
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Clin Epidemiol. 2012 Sep;65(9):989-95
pubmed: 22742913
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
J Am Geriatr Soc. 2000 Nov;48(11):1470-3
pubmed: 11083325
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Drugs Aging. 2018 Jul;35(7):575-587
pubmed: 30006810
Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):901-10
pubmed: 20623513
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
J Am Med Dir Assoc. 2016 Sep 1;17(9):862.e1-9
pubmed: 27473899
J Am Med Dir Assoc. 2020 Feb;21(2):181-187
pubmed: 31926797
BMC Fam Pract. 2015 Oct 14;16:129
pubmed: 26462820
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
BMJ. 2017 Jan 17;356:i6770
pubmed: 28096109
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Lancet. 2017 Apr 29;389(10080):1680-1681
pubmed: 28463129